Trial Profile
A Multi-center, Open-label, Dose-escalation Study to Assess the Pharmacokinetics of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and With Normal Renal Function
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 11 Dec 2020
Price :
$35
*
At a glance
- Drugs Vadimezan (Primary) ; Carboplatin; Docetaxel; Paclitaxel
- Indications Solid tumours
- Focus Pharmacokinetics
- 01 Aug 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 27 Jan 2011 New trial record